Abstract | BACKGROUND: DESIGN AND METHODS: This is a retrospective multicenter analysis of the registry of the Société Française de Greffe de Moelle et de Thérapie Cellulaire, including 143 myeloma patients transplanted between 1999 and 2008. RESULTS: The incidences of cytogenetic abnormalities were 59% for del(13q), 25% for t(4;14), 25% for del(17p) and 4% for t(14;16). When comparing the population carrying an abnormality to that without the same abnormality, no significant difference was found in progression-free survival, overall survival or progression rate. Patients were grouped according to the presence of any of the poor prognosis cytogenetic abnormalities t(4;14), del(17p) or t(14;16) (n=53) or their absence (n=32). No difference in outcomes was observed between these two groups: the 3-year progression-free survival, overall survival and progression rates were 30% versus 17% (P=0.9), 45% versus 39% (P=0.8) and 53% versus 75% (P=0.9), respectively. CONCLUSIONS:
|
Authors | Damien Roos-Weil, Philippe Moreau, Hervé Avet-Loiseau, Jean-Louis Golmard, Mathieu Kuentz, Stéphane Vigouroux, Gérard Socié, Sabine Furst, Jean Soulier, Steven Le Gouill, Sylvie François, Anne Thiebaut, Agnès Buzyn, Natacha Maillard, Ibrahim Yakoub-Agha, Nicole Raus, Jean-Paul Fermand, Mauricette Michallet, Didier Blaise, Nathalie Dhédin, Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) |
Journal | Haematologica
(Haematologica)
Vol. 96
Issue 10
Pg. 1504-11
(Oct 2011)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 21685472
(Publication Type: Journal Article, Multicenter Study)
|
Topics |
- Adult
- Chromosome Aberrations
- Disease Progression
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Multiple Myeloma
(diagnosis, genetics, mortality, therapy)
- Prognosis
- Retrospective Studies
- Transplantation, Homologous
- Treatment Outcome
|